跳至主要内容
临床试验/NCT02589964
NCT02589964终止1 期

Probiotics in the Reduction of Antibiotic Associated Diarrhea and Clostridium Difficile in Pneumonia Patients Within a Community Teaching Hospital

TriHealth Inc.2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2015年3月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
1
试验地点
2
主要终点
Antibiotic Associated Diarrhea

研究概览

简要总结

The study will evaluate the effectiveness of probiotic therapy in reducing the incidence of antibiotic associated diarrhea (AAD) and Clostridium difficile associated diarrhea (CDAD) in pneumonia patients.

详细描述

The study will include patients admitted to Good Samariatan Hospital and placed on the pneumonia order set. After obtaining consent, subjects will be randomized to the proboiotic or placebo group. Subjects will be followed for 21 days after starting the study treatment to determine critical outcomes such as incidence of antibiotic-associated diarrhea and C-Diff. Other outcomes include length of stay, healthcare costs, and death.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Admitted to Good Samaritan Hospital
  • Placed on pneumonia order set

排除标准

  • Patient with inadequate coherency to understand consent
  • Active Diarrhea at admission
  • Non-controlled intestinal disease
  • Documented positive C. difficile infection within the 3 months before enrollment
  • Antibiotic use at hospital admission
  • Immunosuppressive therapy
  • Pregnancy
  • Allergic to ingredients in Florajen-3
  • Allergic to ingredients in placebo
  • Immunocompromised state including:
  • HIV with a low CD4 count
  • Active malignancy receiving chemotherapy
  • Medications including long-term steroids (>2 weeks), and disease modifying biologic agents
  • Acquired immune deficiency
  • Unable to take oral medication
  • Less than 4 doses of probiotic or placebo
  • Taking probiotic in the past 30 days

结局指标

主要结局

Antibiotic Associated Diarrhea

时间窗: 21 days after starting study treatment

Subjects will be asked to keep a diary for 20 days after starting study treatment and will be contacted by a nurse approximately 21 days after starting study treatment

次要结局

  • Length of stay(during hospitalization up to 4 weeks)
  • Mortality(During hospitalization up to 4 weeks)
  • Healthcare costs(During hospitalization up to 4 weeks)
  • Clostridium difficile(21 days after initiating study treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jenni Steinbrunner

Research Specialist

TriHealth Inc.

研究点 (2)

Loading locations...

相似试验